Clinical trials: Proton-therapy
HIV Infections
TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers
The purpose of this study is to investigate the extent by which intake of 20 mg once daily (q.d.) omeprazole influences the levels of TMC278 in the blood after intake of 25 mg q.d..
- Trial name
- NCT01001247
- Testing
- TMC278; Omeprazole
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Tibotec Pharmaceuticals, Ireland
GERD
A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole
The purpose of the study is to demonstrate in patients that oral rabeprazole produces equivalent acid suppression to intravenous pantoprazole on Day 1 of drug administration.
- Trial name
- NCT00378287
- Testing
- rabeprazole sodium
- Volunteers
- 37 people, healthy volunteers welcome
- Sponsor
- Janssen-Ortho Inc., Canada
Healthy
SSP-002358 Drug Interaction Study With Omeprazole
This is a drug interaction study evaluating whether blood plasma concentrations of SSP-002358-base are altered when SSP-002358 is taken together with omeprazole.
- Trial name
- NCT01415349
- Testing
- SSP-002358, SSP-002358 + omeprazole
- Where
- Netherlands
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Shire
Relapsed or Refractory Lymphoma
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPI
An open-label study to determine effect of Itraconazole, Fluconazole, Rifampin, and Rabeprazole on the PK of HMPL-689
- Trial name
- NCT05602597
- Testing
- Itraconazole 200 mg, Fluconazole 400 mg, Rifampin 600 mg
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hutchmed
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Prevention of Recurrent Gastric or Duodenal Ulcers Caused by Low-dose Aspirin With Rabeprazole (E3810) Treatment (Planetarium Study)
The primary objective of this study to evaluate the effect of preventing recurrence of gastric or duodenal ulcers by administering E3810 5 mg or 10 mg tablets once daily or Teprenone 150 mg/day (50 mg three times daily) as a…
- Trial name
- NCT01397448
- Testing
- E3810, Teprenone
- Where
- 49 sites in Japan
- Volunteers
- 472 people
- Sponsor
- Eisai Co., Ltd.
Healthy
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
This study will estimate the effect of food and the proton pump inhibitor, esomeprazole on the pharmacokinetics of crizotinib in a coated microsphere formulation.
- Trial name
- NCT03137134
- Testing
- Crizotinib, Esomeprazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Gastroesophageal Reflux Disease
Pharmacodynamic and Pharmacokinetic Study of E3710 Following Oral Administration to Healthy, Male, Japanese Subjects
The purpose of this study is to investigate the pharmacodynamics (PD) and pharmacokinetics of E3710 following oral administration to Healthy Male Japanese Subjects
- Trial name
- NCT01390714
- Testing
- E3710
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eisai Co., Ltd.
Non-erosive Gastroesophageal Reflux Disease
A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease
To investigate esophageal reflux condition in patients with non-erosive gastroesophageal reflux disease by assessing with a 24-hour esophageal pH monitoring or effects of a 4-week treatment with 5 mg/day or 10 mg/day of E3810…
- Trial name
- NCT00165672
- Testing
- RABEPRAZOLE SODIUM
- Where
- 13 sites in Japan
- Volunteers
- 26 people
- Sponsor
- Eisai Inc.
Gastroesophageal Reflux Disease (GERD)
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
- Trial name
- NCT00394472
- Testing
- AZD3355
- Where
- 38 sites in Australia, Belgium and 6 more
- Volunteers
- 244 people
- Sponsor
- AstraZeneca
Frequent Heartburn
Efficacy/Safety of Lansoprazole in Patients With Frequent Nighttime Heartburn
Heartburn, a burning sensation in the chest or throat, occurs in many individuals when acidic stomach contents move upward into the esophagus from the stomach.
- Trial name
- NCT00701259
- Testing
- Lansoprazole
- Where
- United States
- Volunteers
- 852 people
- Sponsor
- Novartis
Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Effect of Esomeprazole on the Pharmacokinetics of Oral Treprostinil
The purpose of this study is to evaluate the effect of esomeprazole, a proton pump inhibitor, on treprostinil pharmacokinetics.
- Trial name
- NCT00963027
- Testing
- Treprostinil diethanolamine, Esomeprazole
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- United Therapeutics
Duodenal Ulcer
Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection
The purpose of this study is to demonstrate the non-inferior efficacy of TAK-438 versus lansoprazole in the treatment of participants with duodenal ulcer.
- Trial name
- NCT03050359
- Testing
- TAK-438, Lansoprazole, Bismuth-Containing Quadruple Therapy
- Where
- 81 sites in China, Philippines and 2 more
- Volunteers
- 533 people
- Sponsor
- Takeda
Healthy
Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers
This Phase 1, first-in-human, multiple dose-escalation, randomized, double-blinded, placebo-controlled study is evaluating SYNB1934 in healthy volunteers (HV).
- Trial name
- NCT04984525
- Testing
- SYNB1934, SYNB1618
- Where
- United States
- Volunteers
- 106 people, healthy volunteers welcome
- Sponsor
- Synlogic
GERD (Gastroesophageal Reflux Disease)
A Comparison of Cosmos Rx Medication Adherence Platform vs. Pharmacy Fill Adherence Measures
Medication non-adherence is associated with greater morbidity and mortality in chronic disease, and has been estimated to increase healthcare costs by over $170 billion annually in the United States.1 Medication adherence is…
- Trial name
- NCT07712614
- Testing
- Fortiskap
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Cosmos Rx, Inc
Esophagitis
Risk of Cancer Among Pantoprazole Users
The primary objective is to assess whether the risk of gastric cancer is increased in pantoprazole users compared to users of other proton pump inhibitors.
- Trial name
- NCT01322633
- Testing
- Does not apply
- Volunteers
- 61,864 people
- Sponsor
- Pfizer
Death, Sudden, Cardiac
An Observational Study to Assess the Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Users of Proton Pump Inhibitors, and Users of Metoclopramide
The purpose of this observational study is to assess the risk of out-of-hospital Sudden Cardiac (heart) Death (SCD) associated with current use of domperidone compared to current use of a Proton Pump Inhibitor (PPI), current use…
- Trial name
- NCT01907633
- Testing
- No intervention
- Volunteers
- 15,000 people
- Sponsor
- Janssen Research & Development, LLC
Heartburn
Pilot Study To Investigate The Association Between Acid Control And Heartburn Symptoms After Proton Pump Inhibitor Treatment
The purpose of this pilot study is to investigate the association between gastric acid suppression and relief of 24 hour heartburn following treatment with the proton pump inhibitor (PPI) drug esomeprazole in frequent heartburn…
- Trial name
- NCT02708355
- Testing
- Esomeprazole 20 mg
- Where
- 2 sites in United States
- Volunteers
- 55 people
- Sponsor
- Pfizer
Healthy Volunteer
Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor
An open label, multicentre, randomised, 2-cohort, sequential and crossover study to assess the relative oral bioavailability of MT-7117 higher content tablets versus MT-7117 lower content tablets and the pharmacokinetics of…
- Trial name
- MT-7117 BA DDI (NCT03688022)
- Testing
- MT-7117, PPI, Acidic beverage
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Tanabe Pharma America, Inc.
Healthy
Assessing the Effect of a Proton Pump Inhibitor on the Pharmacokinetics of DZD8586 in Healthy Participants (TAI-SHAN21)
This study is a phase 1, open-label, three-period crossover study to evaluate the effect of Rabeprazole, a proton pump inhibitor, on the pharmacokinetics of DZD8586 (Birelentinib) under fasted and fed conditions in healthy…
- Trial name
- NCT07888569
- Testing
- DZD8586, Rabeprazole
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dizal Pharmaceuticals
Solid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device.
- Trial name
- NCT07153094
- Testing
- Proton Beam Therapy (PBT)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ion Beam Applications